CA-TALKDESK
21.2.2024 15:01:30 CET | Business Wire | Press release
Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, today announced that Albert (Al) Caravelli, an accomplished executive experienced in transforming sales and alliances organizations at some of the world’s leading software companies, has joined the company as senior vice president of Alliances and Partners.
In this role, Caravelli is responsible for expanding and nurturing Talkdesk’s growing ecosystem of strategic technology alliance partners, global system integrators, and global service providers.
Caravelli comes to Talkdesk following nearly nine years at cloud security company Zscaler, where he most recently served as global vice president of strategic alliances and advisory firms, responsible for leading Zscaler’s go-to-market strategy and execution. During this time, he was instrumental in the formation of strategic alliances with multiple companies, including Accenture, Capgemini, Deloitte, HCL, Infosys, AT&T, BT, Cognizant, Deutsche Telekom, OBS, Telefonica, TCS, TechMahindra, LTIM, Verizon, Vodafone, and Wipro.
Before his tenure at Zscaler, Caravelli served as senior director of worldwide global alliances at HP Software, where he drove the transformation of the global alliances function, resulting in better strategic engagement with partners and new joint offerings. He has also served in alliances leadership at Jive Software and Mercury Interactive and in sales roles at Asera, Nielsen Claritas, and The Nielsen Company. Caravelli started his career as a sales manager at Nestle.
A former international athlete, Caravelli continues to serve as a technical advisor and guest commentator for the HSBC World Rugby Sevens, which supports local rugby unions in preparing and qualifying for the Olympics and other competitions. He was the former head coach for USA Rugby and the Philippines Volcanoes National Teams. Caravelli volunteers with the Special Olympics and Wounded Warriors.
He holds a bachelor’s degree in computer science from the University of California, Los Angeles (UCLA) and a Master of Business Administration (MBA) from the UCLA Anderson School of Management.
Supporting Quotes
Tiago Paiva, founder and chief executive officer of Talkdesk, commented: “In the last year, we have added phenomenal talent to our leadership team. Al brings a wealth of experience to help Talkdesk accelerate its corporate strategy. His expertise in building and guiding exceptional partner and alliance teams will be vital as we execute our vision of reaching $1 billion in revenue, scale globally, and transform the contact center industry.”
Al Caravelli, senior vice president of Strategic Alliances and Partners at Talkdesk, said: “I’ve admired the success of Talkdesk for years. When the opportunity to join the leadership team arose, I was eager to start a conversation. As I spoke with Tiago and others throughout the organization, it was clear that my experience and strategic playbook dovetailed nicely with the company’s business goals. I look forward to getting to know the partner ecosystem and aligning on new strategies and initiatives.”
Rex Thexton, senior managing director at Accenture, stated: “I've had the pleasure of working closely with Al in recent years. I have witnessed first-hand how his experience building and strengthening alliance and partner programs helps companies accelerate their revenue and strategic goals. He will be a tremendous asset to the Talkdesk leadership team.”
Sherry Vaswani, group chief executive officer of Xalient, said: “I've had the opportunity to work first-hand with Al for the last seven years. We’ve called on customers together, and we’ve planned and executed campaigns that led to many joint customer successes. Al helped develop the partnership between Zscaler and Xalient, appreciating the needs that we have at all stages of our expansion and proactively supporting us to achieve significant growth. I know he will add huge value to Talkdesk.”
About Talkdesk
Talkdesk® is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible, and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do, and our investment in the highest levels of security and reliability for our products, make us second to none in the industry. Improve customer experiences, increase efficiency, and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220064868/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom